Urologie und Urogynäkologie Archives - Laborie

Urologie und Urogynäkologie

Laborie’s Optilume® Drug-Coated Balloon for Stricture Secures Coverage from BCBS of Michigan

Effective July 1, 2025, Blue Cross Blue Shield of Michigan (BCBSM) has issued a new medical policy under CPT code 52284, extending coverage for Laborie Medical Technologies’ Optilume® Urethral Drug-Coated Balloon for Stricture to eligible Commercial HMO members. This new coverage reinforces Laborie’s ongoing commitment to enhancing patient outcomes through wider access to evidence-based medical technologies.

Urologie und Urogynäkologie

Three-Year Data from ROBUST III Confirms Long-Term Durability of Optilume® Drug-Coated Balloon for Recurrent Urethral Strictures

Laborie Medical Technologies Corp. (Laborie), a global leader in diagnostic and therapeutic urology, announced the publication of three-year outcomes from the ROBUST III randomized controlled trial in the Journal of Endourology. The results underscore the long-term durability and safety of the Optilume® Drug-Coated Balloon (DCB) as a minimally invasive treatment for recurrent anterior urethral strictures in men.

Urologie und Urogynäkologie

Optilume Drug-Coated Balloon Shows Long-Term Efficacy for Urethral Strictures: Five-Year Data Published in the Journal of Urology

Unkategorisiert |

Urologie und Urogynäkologie

Optilume® BPH Catheter System Issued Category 1 CPT Code by American Medical Association

Urologie und Urogynäkologie

Laborie Unveils Positive Study Results for Optilume® BPH Catheter System

Laborie announced positive 2-year and 5-year results from studies for its Optilume® BPH Catheter System.

Urologie und Urogynäkologie

NHS England Reimburses Optilume® Urethral Drug Coated Balloon as Part of the Specialised Services Device Programme

Laborie welcomed the inclusion of Optilume® Urethral Drug-Coated Balloon (DCB) into the National Health Service (NHS) Specialized Services Device Programme (SSDP) as of April 1, 2024.

Urologie und Urogynäkologie

Laborie Medical Technologies Invests in iO Urology and the CarePath Uroflow Device

Laborie Medical Technologies  announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.

Unkategorisiert |

Urologie und Urogynäkologie

Laborie Medical Technologies Acquires Urotronic

Urotronic joins Laborie as part of a long-term growth strategy for the Portsmouth-based medical device company. Urotronic’s Optilume® BPH Catheter System, a unique minimally invasive surgical therapy (MIST), is a paradigm shift for patients and clinicians in global interventional urology.

Unkategorisiert |

Urologie und Urogynäkologie

Laborie Medical Technologies Announces Agreement to Acquire Urotronic for up to $600 Million

Acquisition expands urology portfolio and demonstrates Laborie’s commitment to providing proven, innovative solutions to physicians and patients globally

Urologie und Urogynäkologie

Laborie’s Optilume® Issued Category 1 CPT Code by American Medical Association

Seite 1 von 312 3 »